📊 Big Pharma H1 2024 revenue evolution

Solid 1st half of the year for large pharma with 90% upgrading their 2024 outlook during earnings releases.

Half of large pharma companies growing at rates over 8%.

🥇 Eli Lilly and Company exceptional growth due to the continued success of Mounjaro and Zepbound.

🟢 Strong performance for Novo Nordisk but below Lilly, though supply issues with Wegovy and Ozempic limited growth.

🔴 Pfizer still suffers from Covid-related sales loss but is boosted by higher gross margins and improved EPS forecasts.

🟡 Mixed outcomes for Johnson & Johnson but solid growth in pharma is expected.

🟡 Roche surpassed expectations, fueled by robust performance in pharma and diagnostics.

🟢 Strong growth for Merck driven by Keytruda and Winrevair.

🟡 Positive results for AbbVie thanks to Skyrizi and Rinvoq.

🟢 Steady growth in revenues for Novartis with an upward revision in FY24 guidance.

🟢 Bristol Myers Squibb had a strong Q2 led by Revlimid and new launches like Camzyos.

🟢 Solid results for Sanofi in BioPharma and Consumer Health, but Vaccines faced challenges.

🟢 Strong Q2 for AstraZeneca powered by solid sales in Oncology and CVRM.

🟢 Strong performance in Specialty and General Medicines for GSK; minor shortfall in Vaccines.

🟡 Gilead Sciences' revenue and EPS exceeding expectations, led by liver disease treatments.

🟢 Amgen's revenue growth driven by strong product sales, though operating costs increased.

Source : Company Q1 & Q2 reports & Atacana Group analysis 👏